Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy
2024

Inhibiting Tyrosine Kinase 2 Improves Kidney Issues in Antiphospholipid Syndrome

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): Kuo-Tung Tang, Yu-Sin Chen, Tzu-Ting Chen, Ya-Hsuan Chao, Shu-Ping Kung, Der-Yuan Chen, Chi-Chien Lin

Primary Institution: National Chung Hsing University

Hypothesis

Type I interferon is crucial in the generation of APS nephropathy.

Conclusion

The study shows that inhibiting Tyk2 can improve kidney function in a mouse model of APS nephropathy.

Supporting Evidence

  • The Tyk2 inhibitor reversed the elevation of blood urea nitrogen and microalbuminuria in the murine model of APS nephropathy.
  • Pathological vascular changes in the kidney were reversed as judged by electron microscopy.
  • An increased expression of IFN signature in the kidneys of APS mice was found, which was reversed by Tyk2 inhibition.

Takeaway

This study found that a new medicine can help fix kidney problems in mice with a disease that causes blood clots.

Methodology

The study used a mouse model of APS nephropathy and administered a Tyk2 inhibitor to evaluate its effects on kidney function.

Limitations

The study was conducted in mice, and further human studies are needed.

Participant Demographics

Six-week-old female BALB/c mice were used in the study.

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/mi/5568822

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication